Cediranib
Digestive System Carcinoma
M.D. Anderson Cancer CenterSmall moleculePhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 81/ 100
Competitive context
10 Active assets in the Digestive System Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Temsirolimus M.D. Anderson Cancer Center | Phase 1 | CC |
Cetuximab M.D. Anderson Cancer Center | Phase 1 | CC |
(+)-VINCRISTINE M.D. Anderson Cancer Center | Phase 1 | CC |
Valproic Acid M.D. Anderson Cancer Center | Phase 1 | CC |
apd356 Ohio State University Comprehensive Cancer Center | Phase 1 | CC |
View all 15 →
Same molecule, other indications
Cediranib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →